{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:11:37Z","timestamp":1761808297288},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1442","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"S61-S67","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : complications de la chirurgie"],"prefix":"10.1016","volume":"98","author":[{"given":"Christine","family":"Chevreau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"M\u00e9jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1442_bib0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0010","series-title":"Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BRiTE observational colon study.","author":"Kozloff","year":"2008"},{"key":"10.1684\/bdc.2011.1442_bib0015","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1442_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1442_bib0030","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1442_bib0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1442_bib0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0045","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1200\/JCO.2008.17.7857","article-title":"Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases","volume":"26","author":"Kesmodel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jamcollsurg.2007.06.290","article-title":"Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases","volume":"206","author":"Reddy","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1684\/bdc.2011.1442_bib0055","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma","volume":"27","author":"Jonasch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.juro.2008.03.047","article-title":"Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma","volume":"180","author":"Margulis","year":"2008","journal-title":"J Urol"},{"key":"10.1684\/bdc.2011.1442_bib0065","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2009.24.7759","article-title":"Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma","volume":"28","author":"Cowey","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0070","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.urology.2008.01.088","article-title":"Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy","volume":"72","author":"Amin","year":"2008","journal-title":"Urology"},{"key":"10.1684\/bdc.2011.1442_bib0075","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.juro.2008.10.001","article-title":"Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma","volume":"181","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1684\/bdc.2011.1442_bib0080","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.juro.2009.05.014","article-title":"Surgical resection of renal cell carcinoma after targeted therapy","volume":"182","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1684\/bdc.2011.1442_bib0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jvir.2009.01.022","article-title":"Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy","volume":"20","author":"Zawacki","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"10.1684\/bdc.2011.1442_bib0090","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","article-title":"Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events","volume":"33","author":"Hurwitz","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/annonc\/mdm508","article-title":"Management of bevacizumab-associated bowel perforation: a case series and review of the literature","volume":"19","author":"Badgwell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.21447","article-title":"Antiangiogenic agents and late anastomotic complications","volume":"101","author":"Deshaies","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0105","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","article-title":"Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0110","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/annonc\/mdq564","article-title":"The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer","volume":"22","author":"Powles","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","article-title":"Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care","volume":"11","author":"Bose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0120","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1200\/JCO.2005.23.754","article-title":"Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab","volume":"23","author":"Ellis","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0125","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1442_bib0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.gcb.2007.11.001","article-title":"Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations","volume":"32","author":"Boige","year":"2008","journal-title":"Gastroenterol Clin Biol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:35:17Z","timestamp":1602491717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305269"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1442","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}